Cerevel Therapeutics Holdings Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm a large cap biotech analyst at JPMorgan. And we're continuing the conference this morning with Cerevel. A little different format this year, so we're not going to do the whole switching rooms thing for Q&A.
After Tony's presentation, we're going to go straight into Q&A in this room. There's 2 ways to ask a question, you can raise your hands, someone will bring you a mic or you can submit your questions electronically, and send it to an iPad, and I'll read the question for you.
So with that, let me pass it over to Cerevel CEO, Tony Coles.
Thank you, Jess, and good morning, everyone. It's certainly terrific to be back in San Francisco for one of the first large in-person JPMorgan. I'm happy to be here and to be with you this morning to tell you the tale -- the improbable story of the company of Cerevel that is really working to do
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
